UnknownNot Applicable

The Impact of the Use of Recombinant Human Growth Hormone on ADHD Characteristics in Children and Adolescents

Israel100 participantsStarted 2015-01

Plain-language summary

Analysis of the short-and long-term impact of recombinant growth hormone on attention deficit and hyperactivity charachteristics in children and adolescents. This will be examined in children prior to GH therapy and 3, 6 and 12 months during treatment, by filling validated questionnaires (Vanderbilt rating scales) evaluating ADHD. Data will be compared to healthy control group.

Who can participate

Age range6 Years – 16 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Children over the age of 6 years, and less than 16 years * Children eligible for rhGH treatment according to the following Food and Drug Administration approved indications; Small for gesational age, Idioapathic short stature, GH deficiency and chronic renal failure. * Consent of parents / guardian to participate in research Exclusion Criteria: * \- Under the age of 6 years and above 16 years * Previously diagnosed with neurocognitive disease * Previously diagnosed with specific syndromes: Prader-willi syndrome, Turner * Previously diagnosed with Attention Deficit/Hyperactivity disorder

What they're measuring

ADHD criteria

Timeframe: 12 months

Trial details

NCT IDNCT02973061

SponsorAssaf-Harofeh Medical Center

Sponsor typeOTHER_GOV

Study typeOBSERVATIONAL

Primary completion2024-12

Contact for this trial

Marianna Rachmiel, md

97289542007 mariannar@asaf.health.gov.il

View on ClinicalTrials.gov More Growth Hormone Deficiency trials